Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122633 | 1.00 | USP2 (0.73) | USP2LMNAALDH1A1POLBGAA | |
| SCHEMBL1229961 | 0.98 | USP2 (0.69) | USP2LMNAALDH1A1POLBGAA | |
| SCHEMBL421626 | 0.94 | USP2 (0.63) | USP2LMNAALDH1A1POLBGAA | |
| SCHEMBL21625031 | 0.83 | GAA (0.64) | USP2ALDH1A1POLBGAAHTT | |
| SCHEMBL3568679 | 0.81 | POLB (0.68) | USP2LMNAPOLBHTTMEN1 | |
| SCHEMBL391396 | 0.81 | POLB (0.68) | USP2LMNAALDH1A1POLBGAA | |
| SCHEMBL5657050 | 0.81 | LMNA (0.61) | USP2LMNAALDH1A1POLBHTT | |
| SCHEMBL4729326 | 0.81 | MAPT (0.64) | USP2LMNAALDH1A1MAPT | |
| SCHEMBL1902263 | 0.79 | ALDH1A1 (0.85) | USP2LMNAALDH1A1POLBGAA | |
| SCHEMBL10445162 | 0.79 | ALDH1A1 (0.85) | USP2LMNAALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | claimed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | claimed |
| CN-106636043-A | Preparation method of protease | 广州立白企业集团有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | claimed |
| EP-2969003-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | The University of Chicago (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-8853207-B2 | Heterocyclic pyrazole compounds, method for preparing the same and use thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-10-07 | — | — | US | claimed |
| WO-2014144710-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-09-18 | — | — | WO | claimed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | claimed |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-10-17 | — | — | US | claimed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | claimed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1546186-A4 | METHOD FOR SYNTHESIZING PEPTIDES | A & PEP INC (KR) | 2006-02-08 | — | — | EP | claimed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1546186-A1 | METHOD FOR SYNTHESIZING PEPTIDES | A & Pep Inc. (KR) | 2005-06-29 | — | — | EP | claimed |
| WO-2004018501-A1 | METHOD FOR SYNTHESIZING PEPTIDES | A & PEP INC. (KR) | 2004-03-04 | — | — | WO | claimed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | USP2 1021/4885LMNA 4184/4885ALDH1A1 3088/4885 |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | USP2 2421/4885LMNA 1893/4885ALDH1A1 2647/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | USP2 2541/4885LMNA 4027/4885ALDH1A1 4156/4885 |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | USP2 4014/4885LMNA 2227/4885ALDH1A1 1944/4885 |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | RET, FLT3, FGFR1 | USP2 2385/4885LMNA 3752/4885ALDH1A1 1491/4885 |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | USP2 2421/4885LMNA 1893/4885ALDH1A1 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.